Junemann_edit.qxp 16/10/08 01:55 Page 66
Overactive Bladder
Table 6: Efficacy of Fesoterodine 4mg versus Fesoterodine 8mg Table 7: Patient-reported Outcomes Assessed Using the
at 12 Weeks King’s Health Questionnaire
Fesoterodine
Fesoterodine
Baseline Mean Placebo 4mg 8mg
Improvement versus baseline (absolute value) Placebo 4mg 8mg
(Median % Change)
Severity/coping behaviour 7.4 11.3* 13.7*
†
Micturitions/24 hours 12.0–12.2 -10.0 -15.5* 17.1*
Emotions 9.1 12.4* 15.3*
†
(n=545) (n=532) (n=543)
Role limitations 12.5 18.5* 21.4*
UUI episodes/24 hours 3.7–3.9 -42.9 -75.0* -83.3*
†
Physical limitations 11.4 17.2* 19.6*
(n=416) (n=427) (n=441)
Social limitations 7.9 11.6* 13.8*
% positive treatment 49 69* 77*
†
Sleep/energy 7.8 10.7* 12.3*
responses (n=545) (n=532) (n=543)
Personal relationship 5.9 7.8 9.6*
MVV/micturition 155–156 9.0 22.2* 33.6*
†
Incontinence impact 14.2 19.6* 22.5*
(n=543) (n=531) (n=542)
General health perception 2.4 2.9 2.6
Continent days/ 0.7–0.8 1.8 2.6* 3.1*
†
*p<0.01 versus placebo; † p<0.05 versus fesoterodine 4mg.
24 hours (n=416) (n=427) (n=441) Adapted from Kelleher et al., 2008.
20
*p<0.01 versus placebo; † p<0.05 versus fesoterodine 4mg.
MVV = mean voided volume; UUI = urgency urinary incontinence.
Table 8: Treatment-related Adverse Events Occurring in 2% of
Adapted from Khullar et al., 2008.
19
Patients and More Frequently than with Placebo
Figure 3: Fesoterodine Dose–Response Relationship in Adverse Events Placebo Tolterodine ER 4mg Fesoterodine 8mg
Reduction of Urgency Urinary Incontinence Episodes
(n=283) (n=290) (n = 287)
%% %
Dry mouth 7.1 16.9 33.8
Placebo
4 Fesoterodine 4mg
Constipation 1.4 2.8 4.5
Fesoterodine 8mg
Dry eye 0 <1 4.2
Fatigue <1 0 2.1
Nausea <1 2.1 1.4
3
Increased alanine <1 0 2.1
*
aminotransferase
*
2
*
Dry throat 0 1 2.8
*
Nasopharyngitis 2.5 3.4 1.7
Adapted from Chapple et al., 2008.
18
Number of UUI episodes per 24 hours
*
*
1
BL 2 weeks 8 weeks 12 weeks 8mg compared with tolterodine ER 4mg (p<0.05) (see Table 5).
EOT
Fesoterodine 8mg also augmented the response rate significantly
*p<0.001 versus placebo and two weeks and at end of treatment (EOT). † p<0.05 versus
compared with tolterodine ER 4mg (p<0.05), and significantly
fesoterodine 4mg.
BL = baseline; UUI = urgency urinary incontinence.
increased MVV/micturition compared with tolterodine ER 4mg
Adapted from Khullar et al., 2008.
19
(p<0.05). Finally, fesoterodine 8mg was significantly more efficacious
than tolterodine in elevating the number of continent days (p<0.05)
undertaken to determine whether there were statistically significant (see Table 5). Collectively, these findings clearly showed that the
differences in efficacy between the two doses (4 and 8mg) of
fesoterodine
19
and to evaluate the effects and possible differences
between the two doses of fesoterodine on HRQoL.
20
Notably, the fesoterodine 8mg dose
In SP583, patients with OAB in both the active treatment and active
performed significantly better than
control groups showed significant improvements in most bladder diary
fesoterodine 4mg in improving all
variables compared with placebo. Fesoterodine 8mg was statistically
diary variables (p<0.05), except the
better than tolterodine ER 4mg in improving diary variables such as
UUI episodes per 24 hours, UUI episodes per 24 hours, treatment frequency of micturitions.
response, MVV/micturition, continent days per week and severe
urgency with UUI (p<0.05 for all parameters).
18
Figure 2 shows the
median percentage change from baseline in severe urgency and UUI maximum recommended dose of fesoterodine (8mg) was significantly
episodes per 24 hours obtained with placebo, tolterodine ER 4mg and more effective than the recommended dose of tolterodine ER (4mg) in
fesoterodine 8mg. In the fesoterodine 8mg group, the median improving a number of OAB outcomes.
percentage change in number of severe urgency and UUI episodes per
24-hour period from baseline to end of treatment was significantly The pooled analysis that compared the efficacy of fesoterodine 4 and
greater than that seen with either tolterodine ER 4mg or placebo 8mg also yielded interesting results, which were recently published by
(p<0.05 for both) (see Figure 2). Khullar et al.
19
Both doses of fesoterodine achieved rapid and sustained
treatment response rates at two weeks, and this response was sustained
In addition, the median percentage change from baseline in UUI throughout the study. Notably, the fesoterodine 8mg dose performed
episodes per 24 hours was significantly reduced with fesoterodine significantly better than fesoterodine 4mg in improving all diary
66 EUROPEAN UROLOGICAL REVIEW
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131